Table 1

Alterations of Mdmx, Mdm2 and p53 in 115 primary breast cancers
Characteristics Patients no. (%) Mdmx amplification Mdm2 overexpression p53 disfunction
no. (%) P no. (%) P no. (%) P
Tumor size1 36 (31.3%) 22 (61.1%) 19 (41.3%) 8 (22.2%)
d≦20 mm 66 (57.4%) 35 (53.0%) 0.710 21 (31.8%) 0.301 29 (47.5%) 0.009
50 mm > =d > 20 mm 13 (11.3%) 8 (61.5%) 4 (30.8%) 7 (53.8%)
d > 50 mm
Grade
I 9 (7.8%) 7 (77.8%) 5 (55.6%) 0.738 0 (0) 0.001
II 67 (58.3%) 38 (56.7%) 0.244 22 (32.8%) 22 (32.8)
III 39 (33.9%) 20 (51.3%) 17 (43.6%) 22 (56.4%)
Nodal status2 0.122 0.348
N 51 (44.3%) 31 (60.8%) 0.453 24 (47.1%) 18 (35.3%)
N+ 64 (55.7%) 34 (53.1%) 20 (31.2%) 26 (40.6%)
ER status 0.116 0.016
Negative 42 (36.5%) 24 (57.1%) 1.000 12 (28.6%) 22 (52.4%)
Positive 73 (63.5%) 41 (56.2%) 32 (43.8%) 22 (30.1%)
PR status 4 0.241 0.185
Negative 5 (39.1%) 22 (48.9%) 0.248 14 (31.1%) 20 (44.4%)
Positive 70 (60.9%) 43 (61.4%) 30 (42.9%) 24 (34.3%)
HER-2 status 0.330 0.305
Negative 93 (80.9%) 54 (58.1%) 0.633 38 (40.9%) 37 (40.7%)
Positive 22 (19.1%) 11 (50.0%) 6 (27.3%) 7 (31.8%)
Ki67 expression 1.000 0.006
Low 44 (38.3%) 28 (63.6%) 0.251 17 (38.6%) 10 (22.7%)
High 71 (61.7%) 37 (52.1%) 27 (38.0%) 34 (47.9%)
Mdmx amplification 0.176 0.033
Yes 65 (56.5%) ___ ___ 21 19
No 50 (43.5%) 23 25
Mdm2 overexpression ___ ___ ___ ___ 0.018
Yes 44 (38.3%) 11
No 71 (98.3%) 33

1d, diameter.

2N0, node metastasis negative; N+, node metastasis positive.

Yu et al.

Yu et al. Diagnostic Pathology 2014 9:71   doi:10.1186/1746-1596-9-71

Open Data